Table 2.
Baseline characteristics of 149 patients submitted to liver resection for huge (≥10 cm) hepatocellular carcinoma
| Total cohort (n = 149) | BCLC class A (n = 48, 32.2%) | BCLC class B (n = 56, 37.6%) | BCLC class C (n = 45, 30.2%) | P-valuea | |
|---|---|---|---|---|---|
| Patient characteristics | |||||
| Age, years, mean ± SD | 58 ± 15 | 58 ± 16 | 59 ± 16.5 | 57 ± 12 | 0.522 |
| Male/female, n (%) | 117 (78.5%)/32 (21.5%) | 36 (75%)/12 (25%) | 48 (85.7%)/8 (14.3%) | 33 (73.3%)/12 (26.7%) | 0.248 |
| CCI | |||||
| Weighted index, mean ± SD | 0.26 ± 0.49 | 0.28 ± 0.5 | 0.19 ± 0.4 | 0.33 ± 0.5 | 0.353 |
| Age-adjusted index, mean ± SD | 1.90 ± 1.3 | 1.83 ± 1.1 | 1.77 ± 1.1 | 1.33 ± 0.2 | 0.136 |
| Aetiology of liver disease, n (%) | |||||
| HBV infection | 39 (26.2%) | 14 (29.2%) | 10 (17.9%) | 15 (33.3%) | 0.302 |
| HCV infection | 9 (6%) | 2 (4.2%) | 3 (5.4%) | 4 (8.9%) | |
| Alcohol | 10 (6.7%) | 4 (8.3%) | 3 (5.4%) | 3 (6.7%) | |
| Metabolic syndrome | 6 (4%) | 0 | 5 (8.9%) | 1 (2.2%) | |
| Haemochromatosis | 1 (0.7%) | 0 | 1 (1.8%) | 0 | |
| No liver disease | 84 (56.4%) | 28 (58.3%) | 34 (60.7%) | 22 (48.9%) | |
| Status of underlying liver, n (%) | |||||
| Normal | 48 (32.2%) | 17 (35.4%) | 20 (35.7%) | 11 (24.4%) | |
| Chronic hepatitis or fibrosis | 78 (52.3%) | 25 (52.1%) | 26 (46.4%) | 27 (60%) | |
| Cirrhosis | 23 (15.4%) | 6 (12.5%) | 10 (17.9%) | 7 (15.6%) | |
| Portal vein embolization | 10 (6.7%) | 3 (6.3%) | 4 (7.1%) | 3 (6.7%) | 0.984 |
| Tumour characteristics | |||||
| Macroscopic vascular invasion at diagnosis | 45 (30.2%) | 0 | 0 | 45 (100%) | 0.0001 |
| Tumour size at diagnosis, mm, mean ± SD | 126 ± 30.9 | 136 ± 37.3 | 143 ± 36.4 | 164 ± 48.3 | 0.0082 |
| Tumour number at diagnosis, mean ± SD | 1.7 ± 2.8 | 1 | 2.4 ± 4.4 | 1.5 ± 1.1 | 0.0002 |
| α-fetoprotein, ng/ml, median (range) | 31.5 (1–1 140 000) | 14.5 (1–608 100) | 28 (1–150 000) | 500 (1–1 140 000) | 0.01 |
| Preoperative blood tests | |||||
| Total bilirubin, μmol/l, mean ± SD | 16.78 ± 34.84 | 12.78 ± 7.13 | 20.63 ± 56.97 | 16.41 ± 7.97 | 0.013 |
| AST, IU/l, mean ± SD | 83.57 ± 93.30 | 59.40 ± 80.50 | 73.55 ± 92.94 | 119.40 ± 97.05 | <0.0001 |
| ALT, IU/l, mean ± SD | 53.70 ± 62.40 | 47.73 ± 78.15 | 47.33 ± 36.19 | 66.91 ± 66.56 | 0.007 |
| Platelet count per ml, mean ± SD | 294 000 ± 250.2 | 267 500 ± 102.5 | 335 500 ± 392.3 | 276 500 ± 130.9 | 0.916 |
a
Chi-squared or Kruskal–Wallis test as appropriate.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; CCI, Charlson Comorbidity Index; HBV, hepatitis B virus; HCV, hepatitis C virus; SD, standard deviation.